FDA grants orphan drug designation to myelodysplastic syndrome drug

10/6/2013 | Pharmaceutical Business Review Online

Cornerstone Pharmaceuticals announced that CPI-613, its myelodysplastic syndrome drug, has been given orphan drug status by the FDA. The altered energy metabolism directed drug candidate is in Phase I, I/II and Phase II trials focused on hematologic malignancies and solid tumors.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY